Acumen Pharma Trial Timelines, Cash Position

 

• Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026
  
  

• Expect decision to advance an oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026
  
  

• Cash, cash equivalents and marketable securities of $166.2 million as of June 30, 2025, expected to support current clinical and operational activities into early 2027

Anticipated Milestones

• The Company expects topline results from ALTITUDE-AD, a Phase 2 study to investigate sabirnetug for the treatment of early Alzheimer’s disease, in late 2026.

• The Company expects non-clinical data to support the development of an EBD therapy in early 2026, at which point Acumen has an exclusive right to exercise its option to develop up to two development candidates as part of its partnership with JCR.
  
  

Second Quarter 2025 Financial Results

• Cash Balance. As of June 30, 2025, cash, cash equivalents and marketable securities totaled $166.2 million compared to cash, cash equivalents and marketable securities of $197.9 million as of March 31, 2025. The decrease in cash is related to funding ongoing operations. Cash is expected to support current clinical and operational activities into early 2027. 

Conference Call Details

Acumen will host a conference call and live audio webcast today, August 12, 2025, at 8:00 a.m. ET.

To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.

The webcast audio will be available via this link.

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.

https://finance.yahoo.com/news/acumen-pharmaceuticals-reports-second-quarter-110000834.html

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

 On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials, previously referred to as AMP-002.

Iron sucrose injection is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD).

“We look forward to launching our iron sucrose injection in the third quarter of 2025,” said Jack Zhang, Amphastar’s President and CEO.

According to IQVIA, the U.S. sales for Venofer (branded sucrose injection) were approximately $513 million for the 12 months ended June 30, 2025.

Amphastar currently has three ANDAs and one biosimilar insulin candidate filed with the FDA, targeting products with a combined market size exceeding $2.5 billion, along with three biosimilar products in development targeting products with a market size exceeding $6 billion, and two generic products in development targeting products with a market size of over $1 billion.

Concurrently, the FDA approved Viatris Inc.’s (NASDAQ:VTRS) Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia (IDA) in adult and pediatric patients (2 years of age and older) with chronic kidney disease.

Needham said AMP-002 could target about two-thirds of the Venofer market, the part not controlled by Fresenius Medical Care AG (NYSE:FMS), in the dialysis space, potentially bringing Amphastar $80 million to $100 million in sales.

Analyst Serge Belanger upgraded Amphastar to a Buy rating from Hold, with a price forecast of $36, citing an attractive valuation level and a new top-line contributor that should help the company meet/surpass growth expectations for 2025 and 2026.

Needham notes that it’s unknown whether the FDA is reviewing other Venofer ANDA applications, but AMP-002 and Viatris hold six months of exclusivity. Because the drug is complex, only a few generic companies can develop and produce it.

“Amphastar expects to launch ASAP, likely before the end of August, which should lead to meaningful sales as early as the third quarter of 2025,” the analyst said.

Last week, Amphastar Pharma reported adjusted earnings of 85 cents, beating the consensus of 76 cents.

Sales fell 4% year over year to $174.41 million, beating the consensus of $174.25 million.

On Tuesday,  Amphastar Pharmaceuticals announced an exclusive license agreement with Nanjing Anji Biotechnology to develop, manufacture, use, and commercialize three proprietary peptides in the U.S. and Canada.

The first product is based on Anji’s discovery of an endogenous peptide that demonstrates a novel mechanism of action that potentially suppresses the growth and metastasis of multiple poorly treated cancers.

Amphastar made an earnest money payment $0.75 million and an upfront payment of $5.25 million to Anji.

The agreement also includes additional potential development milestone payments of up to $42 million and sales milestone payments of up to $225 million.

Anji may receive up to $453 million in total payments over the agreement’s lifetime.

https://finance.yahoo.com/news/amphastar-secures-fda-nod-iron-173858167.html

Liquidia YUTREPIA Hits 900 Patient Prescriptions, Reports Q2 2025 Earnings

Liquidia Corporation (NASDAQ: LQDA) reported significant progress in Q2 2025, highlighted by the successful launch of YUTREPIA™ (treprostinil) inhalation powder. Following FDA approval in May 2025, the drug achieved over 900 unique patient prescriptions and 550 patient starts within 11 weeks for treating PAH and PH-ILD.

The company's interim ASCENT trial data showed promising results, with patients demonstrating a median improvement in six-minute walk distance of 31.5 meters at Week 16. Financially, Liquidia reported $173.4M in cash, generated $6.5M in product revenue, and recorded a net loss of $41.6M ($0.49 per share) for Q2 2025.

https://www.stocktitan.net/news/LQDA/liquidia-corporation-reports-second-quarter-2025-financial-results-68wiwnb4bmon.html

X4 Pharma $60 Million Equity Financing with Concurrent Changes in Management and Board

 $60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates

Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman, John Volpone as President and David Kirske as Chief Financial Officer

X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it has entered into a securities purchase agreement for a private placement in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $60 million, before deducting placement agent fees and other expenses. The closing of the financing is expected to occur on or about August 13, 2025, subject to customary closing conditions.

Concurrent with the financing and effective immediately, X4 President and Chief Executive Officer Paula Ragan, PhD, and Chief Financial Officer Adam Mostafa have stepped down from their respective roles. Dr. Ragan has also resigned from the Board of Directors, and Michael Wyzga has transitioned from Board Chair to Lead Independent Director. In their place, the X4 Board of Directors has appointed Adam Craig, PhD, as Executive Chair, John Volpone as President, and David Kirske as Chief Financial Officer, effectively immediately. Dr. Craig, Mr. Volpone and Mr. Kirske all previously served at CTI BioPharma and bring deep strategic experience in the life sciences sector as well as key expertise in operational turnarounds.

The financing is being led by Coastlands Capital with support from existing investors Bain Capital Life Sciences and New Enterprise Associates (NEA) and leading life science investors, among them BVF Partners LP, Deep Track Capital, Kalehua Capital, Nantahala Capital, Stonepine Capital Management, and Trails Edge Capital Partners.

Stifel is acting as sole placement agent for the PIPE transaction.

Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE financing, X4 will issue an aggregate of 11,040,776 shares of common stock (or pre-funded warrants to purchase up to 31,234,731 shares of common stock in lieu thereof). The purchase price per share is $1.42 (or $1.419 per pre-funded warrant). The pre-funded warrants have an exercise price of $0.001 per share, are exercisable at any time after their original issuance and will not expire.

https://finance.yahoo.com/news/x4-pharmaceuticals-announces-60-million-110000183.html

180 Life Sciences Discloses Large Ethereum Holdings

 180 Life Sciences Corp. (NASDAQ:ATNF), now operating under the name ETHZilla, experienced a sharp 75% increase in its stock price after announcing it holds 82,186 Ethereum tokens valued at roughly $349 million.

The company revealed it acquired this sizable ETH position at an average cost of $3,806.71 per token. Alongside its cryptocurrency assets, ETHZilla also holds about $238 million in U.S. dollar cash equivalents, resulting in a total treasury value near $587 million.

“At ETHZilla we have put over $350 million in capital to work since the PIPE transaction we completed last week, and have executed on our strategy to rapidly build a differentiated Ethereum treasury vehicle,” said McAndrew Rudisill, Executive Chairman.

The firm plans to keep the recently acquired Ethereum tokens for the long term, staking them through Electric Capital’s proprietary strategies on the Ethereum network to generate yield. Rudisill added that the ETH reserves “will unlock cash flow for our shareholders as we seek to deliver on our on-chain yield generation program.”

According to company filings, ETHZilla has 154.032 million shares outstanding as of August 5, 2025. The company will continue updating investors on its treasury management and yield generation initiatives via public announcements and regulatory disclosures.

https://www.msn.com/en-us/money/topstocks/180-life-sciences-stock-surges-75-following-disclosure-of-large-ethereum-holdings/ar-AA1Kop2r

https://www.marketscreener.com/quote/stock/BAYER-AG-436063/news/Bayer-licensing-agreement-with-Kumquat-in-precision-oncology-50798307/

Cracks Appear In NATO Unity Ahead Of Alaska Summit On Ukraine Territorial Concessions

 Poland’s Prime Minister Donald Tusk, as head of NATO's largest and most well-armed 'eastern flank' country, expressed both concern and cautious optimism on Monday ahead of the upcoming Trump-Putin summit set in Alaska, focused on the war in Ukraine.

Tusk emphasized 'hope' based on Washington's assurance that it would consult its European allies before the talks. "The US has committed to consulting with its European partners ahead of the Alaska meeting," Tusk told a press conference. "I will wait to see the outcome of the talks between Presidents Trump and Putin — I have many concerns, but also some hope." But he also laid out, "The West, including European countries, will not accept Russian demands which simply amount to the seizure of Ukrainian territory."

Tusk further stressed that European leaders were united in their stance on peace negotiations, insisting that Ukraine must be actively included in any talks.

But the reality and elephant in the room is that Moscow is not going to sign onto a final peace settlement and halt its special military operation for nothing short of territorial concessions. It is not going to give up its conquered territories in the Donbas, which it has already declared part of the Russian Federation.

"For Poland and our partners, it is clear: borders cannot be altered by force," Tursk said. "Russia must not gain from its aggression against Ukraine."

The rest of European leadership clearly agrees with him. "As we work towards a sustainable and just peace, international law is clear: All temporarily occupied territories belong to Ukraine," EU foreign policy chief Kaja Kallas has said. "A sustainable peace also means that aggression cannot be rewarded."

And yet, on Sunday NATO Secretary General Mark Rutte actually for the first time opened the door a little on the question of territorial concessions:

"In the end, the issue of the fact that the Russians are controlling at this moment, factually, a part of Ukraine has to be on the table" in any peace talks after the Alaska summit, NATO Secretary General Mark Rutte said on CBS on Sunday.

Rutte said Ukraine’s Western backers "can never accept that in a legal sense," but he suggested that they might tacitly acknowledge Russian control.

He compared it to the way that the U.S. hosted the diplomatic missions of Estonia, Latvia and Lithuania from 1940 to 1991, "acknowledging that the Soviet Union was controlling those territories, but never accepting (it) in a legal sense."

He explained, "When it comes to the entire issue of territory, when it comes to recognition, for example, perhaps in a future agreement, that Russia actually controls part of Ukrainian territory, that must be an actual recognition, not a de jure political recognition."

Watch Turk lay down Europe's red lines on negotiations and what's at stake:

Polish Prime Minister Donald Tusk [@donaldtusk] has warned Russia against getting the idea it can challenge other countries’ borders “with impunity.” He made the comments during a speech at Poland’s Nitro-Chem explosives plant. He also repeated the call for no deals about Ukraine… pic.twitter.com/FyWJarnBNk

— TVP World (@TVPWorld_com) August 11, 2025

Does this reflect Trump's thinking too? If there's any hope whatsoever of making headway with Putin in Alaska, this will indeed have to be on the table. Otherwise there will be no point in talking and the whole meeitng will prove futile in terms of finding a settlement.

Still, what Russia will come a away with is a big diplomatic win regardless - just in the optics alone - in the fact that 'isolated' Putin is given a face-to-face bilateral summit with Trump.

https://www.zerohedge.com/geopolitical/cracks-appear-nato-unity-ahead-alaska-summit-ukraine-territorial-concession-question